Genetic variations associated with cisplatin-induced ototoxicity identified
the ONA take:
The anti-cancer drug cisplatin is widely administered to treat brain cancer and other tumors, but some individuals treated with cisplatin experience severe hearing loss, among other side effects.
But the effect of patients varies widely. The reasons why some patients were affected has not been fully understood, but a group of investigators based at St. Jude Children's Research Hospital feel the cause of rooted in genetic variations.
The research team examined DNA from 238 patients with brain tumors and took into account some 1.7 million common genetic variations, looking for a link to the cisplatin-related hearing loss. This was the first time a possible genetic cause of this side effect had been investigated.
The result: genetic variations in a gene called ACYP2 were linked to as much as a four-fold increase of risk for hearing loss. This association was verified in a separate group of 68 patients after other risk factors, such as radiation treatment or age, were eliminated. Individuals with at least one copy of the ACYP2 variant experienced hearing loss, establishing a link to that genetic variation, but additional individuals also experienced hearing loss so the researchers feel other, not-yet-identified genetic variations are also at play.
This research could be the first step in identified patients receiving cisplatin that are at high risk of hearing loss. Additional research into why the ACYP2 variations actually trigger the hearing is needed.
The anti-cancer drug cisplatin is widely administered to treat brain cancer and other tumors.
Sign Up for Free e-newsletters
- Scalp Cooling With Dignicap May Reduce Alopecia During Chemotherapy for Breast Cancer
- Evolution of HER2-Positive Breast Cancer: Yesterday, Today, and Tomorrow
- Dedicated End-of-Life Education Program Improves Nurses' Care, Patient and Family Satisfaction
- Reflexology, Aromatherapy May Reduce Pain, Anxiety of Brachytherapy for Cervical Cancer
- Oncology Extended Care Clinic Reduced Urgent Cancer-Related ED Visits
- Hair Dyes and Cancer Risk (Fact Sheet)
- Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers
- Hope, Optimism Reduce Psychological Distress in Advanced Cancer
- Mitomycin Extravasation Protocol
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Nursing Practice Change Improved Chemo Administration, But Old Habits Die Hard
- Simple Adjustment Key to Paclitaxel Infusion Protocol That Reduced Hypersensitivity Reactions
- Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Skipping the SICU Post Head and Neck Cancer Surgery May Improve Outcomes
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|